GLP-1 Drugs May Actually Protect Against Gallbladder Problems in Patients with Diabetes and IBD | Research

The takeaway

In 32,000 patients with both diabetes and IBD, those on GLP-1 drugs had significantly fewer gallstone complications than those not taking them — the opposite of what's commonly feared.

Reduced gallstone risk in 32K patients
After propensity matching, patients on semaglutide or tirzepatide had significantly fewer gallstones, cholecystitis, and bile duct stones than unexposed patients with T2DM and IBD

What the researchers found

In a surprising finding, GLP-1 and dual GLP-1/GIP drugs (semaglutide and tirzepatide) were associated with substantially reduced — not increased — risks of gallstone-related complications in patients who have both type 2 diabetes and inflammatory bowel disease. After propensity score matching 32,052 patients (16,026 per group), the GLP-1 group had significantly fewer cases of gallstones (cholelithiasis), gallbladder inflammation (cholecystitis), bile duct stones (choledocholithiasis), and bile duct infection (cholangitis).

This contradicts the general concern that GLP-1 drugs increase gallbladder problems, though this specific population (T2DM + IBD) has a uniquely high baseline risk for biliary complications.

Why it matters

Gallbladder problems are one of the most-discussed side effects of GLP-1 drugs. Clinical trials like SELECT have shown slightly increased gallstone rates. But this study suggests that in patients with IBD — who already face elevated biliary risk — GLP-1 drugs may actually be protective. This could change clinical decision-making for a population that often avoids GLP-1 drugs due to gallbladder concerns.

The numbers in context

n=32,052 matched patients · 16,026 per cohort · reduced cholelithiasis, cholecystitis, choledocholithiasis (all p significant) · cholangitis trended lower (p=0.08) · TrinetX global database

How the study worked

Retrospective cohort study using the TrinetX LIVE global health research network. Adults with coexisting T2DM and IBD were divided into those prescribed semaglutide or tirzepatide versus those with no GLP-1/GIP therapy. Propensity score matching (1:1, caliper 0.1 SD) balanced demographics, comorbidities, GI surgical history, and other diabetes medications. Primary outcomes were identified by ICD-10 codes for gallstone-related conditions.

Who was studied

Adults (≥18 years) with coexisting type 2 diabetes and inflammatory bowel disease

What this study cannot tell us

Retrospective observational design cannot prove causation. ICD-10 codes may miss or misclassify diagnoses. The TrinetX database may have coding biases. The study doesn't distinguish between semaglutide and tirzepatide effects. Patients who tolerate GLP-1 drugs may be inherently healthier than those who don't start them (healthy user bias). The follow-up duration is not specified in the abstract.

How to read the evidence

This is a large, propensity-matched retrospective cohort study using a global health database. While the sample size (32,052) and matching methodology are strengths, it remains observational and cannot prove causation. Healthy user bias and coding limitations are concerns.

When this study was published

Published in 2025. This is a very recent study addressing a current clinical question. As GLP-1 prescriptions continue to grow, more biliary safety data will emerge to confirm or challenge these findings.

The bigger picture

The gallbladder safety profile of GLP-1 drugs has been a clinical concern since early trials showed slight increases in gallstones. But much of the risk may be driven by rapid weight loss itself, not the drugs specifically. This study suggests that in certain populations — particularly those with IBD and chronic inflammation — the anti-inflammatory properties of GLP-1 drugs may actually protect the biliary system. This adds nuance to the blanket 'GLP-1 drugs cause gallbladder problems' narrative.

Questions still open

Is the biliary protection driven by the anti-inflammatory effects of GLP-1 drugs on the IBD, or by a direct effect on biliary motility?
Do these protective findings extend to patients without IBD, or is this specific to the high-risk IBD population?
Does tirzepatide (dual agonist) provide more or less biliary protection than semaglutide (single agonist)?

Common questions

Wait — don't GLP-1 drugs cause gallbladder problems?

Clinical trials have shown a slight increase in gallstones with GLP-1 drugs, likely related to rapid weight loss. But this study found the opposite in patients with IBD and diabetes — GLP-1 drug users had fewer gallbladder complications. The relationship may depend on the patient population, and the anti-inflammatory effects of GLP-1 drugs may be protective in high-risk groups.

Why would patients with IBD be especially vulnerable to gallbladder problems?

Inflammatory bowel disease disrupts bile acid metabolism and increases chronic inflammation — both of which raise the risk of gallstones and other biliary complications. Patients with IBD have higher baseline rates of gallbladder disease than the general population, making the protective finding in this study particularly meaningful.

Read the original research

Guts, Glucose, and Gallbladders: The Protective Role of GLP-1/GIP Receptor Agonists Against Biliary Complications in Patients with Type 2 Diabetes and Inflammatory Bowel Disease.

Journal of clinical medicine, 14(24)

View on PubMed ↗Publisher’s paper ↗

Citation

Kazi, Muhammad Ali Ibrahim; Singh, Sanmeet; Haq, Nowreen. (2025). Guts, Glucose, and Gallbladders: The Protective Role of GLP-1/GIP Receptor Agonists Against Biliary Complications in Patients with Type 2 Diabetes and Inflammatory Bowel Disease.. Journal of clinical medicine, 14(24). https://doi.org/10.3390/jcm14248882